公开(公告)号：WO2015156674A3

公开(公告)日：2015-12-17

申请号：PCT/NL2015050237

申请日：2015-04-10

Applicant: STICHTING NL KANKER INST

Inventor： PEEPER DANIEL SIMON ,  MUELLER JUDITH NADJA

IPC: A61K31/502 ,  A61K31/437 ,  A61K31/506 ,  A61K31/519 ,  A61K35/00 ,  A61K45/06

CPC classification number: A61K31/506 ,  A61K31/437 ,  A61K31/502 ,  A61K31/519 ,  A61K45/06 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57496 ,  G01N2333/4706 ,  G01N2333/91205 ,  A61K2300/00

Abstract: The current disclosure relates to pharmaceutical combinations and compositions useful in the treatment of certain types of cancer. The disclosure also relates to methods for treatment of these types of cancer. In particular, the disclosure relates to the combined use of an inhibitor of a protein of the MAPK/ERK pathway and an inhibitor of specific kinases in the treatment of a cancer, in particular melanoma, in a patient. In an important embodiment, the cancer is characterized by the absence or reduced expression of MITF.

Abstract translation: 本公开涉及可用于治疗某些类型的癌症的药物组合和组合物。 本公开还涉及用于治疗这些类型的癌症的方法。 具体而言，本公开涉及MAPK / ERK途径蛋白质抑制剂与特异性激酶抑制剂在患者癌症特别是黑素瘤治疗中的联合应用。 在一个重要的实施方案中，癌症的特征在于MITF的缺乏或减少的表达。

公开(公告)号：WO2010116003A3

公开(公告)日：2011-02-03

申请号：PCT/EP2010054772

申请日：2010-04-12

Applicant: PAMGENE BV ,  STICHTING NL KANKER INST ,  DE WIJN RICHARD ,  RUIJTENBEEK ROBBY ,  HILHORST MARIA HELENA ,  VAN DEN HEUVEL MICHAEL MARIA ,  KLOMP HOUKE MARIAN

Inventor： DE WIJN RICHARD ,  RUIJTENBEEK ROBBY ,  HILHORST MARIA HELENA ,  VAN DEN HEUVEL MICHAEL MARIA ,  KLOMP HOUKE MARIAN

IPC: G01N33/574 ,  C12Q1/48 ,  G01N33/50 ,  G01N33/52

CPC classification number: G01N33/57423 ,  C12Q1/485 ,  G01N2333/91205 ,  G01N2800/52

Abstract: The present invention relates to a method for determining or predicting the response of a patient diagnosed with non small cell lung cancer to targeted pharmacotherapy. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with non small cell lung cancer to specific medicaments. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles and inhibitions thereof by drugs in samples of said patients.

Abstract translation: 本发明涉及一种用于确定或预测诊断为非小细胞肺癌的患者对靶向药物治疗的反应的方法。 本发明还旨在提供用于预测诊断为非小细胞肺癌的患者对特定药物的反应的方法和装置。 更具体地，本发明提供了通过研究所述患者样品中的药物的磷酸化水平及其特征和抑制来测量激酶活性的方法。

公开(公告)号：WO2013124740A3

公开(公告)日：2014-01-09

申请号：PCT/IB2013000670

申请日：2013-02-25

Applicant: STICHTING VU VUMC ,  STICHTING NL KANKER INST

Inventor： JIMENEZ CORNELIA RAMONA ,  WARMOES MARC OMER ,  PHAM THANG VIET ,  ROTTENBERG SVEN

IPC: G01N33/574

CPC classification number: G01N33/57415 ,  G01N33/57484 ,  G01N2800/52

Abstract: BRCA-deficiency signatures comprising differentially regulated proteins present in BRCA1-deficient tumors, and BRCA-deficiency signatures comprising nucleic acids isolated from BRCA1-deficient tumors, as well as methods of using the same, are disclosed.

Abstract translation: 公开了包含BRCA1缺陷型肿瘤中存在的差异调节蛋白质的BRCA缺陷特征以及包含从BRCA1缺陷型肿瘤分离的核酸的BRCA缺陷型特征，以及使用该BRCA缺陷型鉴定的方法。

公开(公告)号：WO2012038837A2

公开(公告)日：2012-03-29

申请号：PCT/IB2011002759

申请日：2011-09-20

Applicant: STICHTING NL KANKER INST ,  LINN SABINE CHARLOTTE ,  VOLLEBERGH MARIEKE ANNE ,  NEDERLOF PETRA MARLEEN

Inventor： LINN SABINE CHARLOTTE ,  VOLLEBERGH MARIEKE ANNE ,  NEDERLOF PETRA MARLEEN

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/154 ,  C12Q2600/158

Abstract: Methods for optimizing the therapeutic efficacy of anti-cancer therapy by detecting phenotypic genetic traits using comparative genomic hybridization are disclosed.

Abstract translation: 公开了通过使用比较基因组杂交检测表型遗传性状来优化抗癌治疗的治疗功效的方法。

公开(公告)号：WO2011048498A3

公开(公告)日：2011-06-23

申请号：PCT/IB2010002892

申请日：2010-10-19

Applicant: STICHTING NL KANKER INST ,  LINN SABINE CHARLOTTE ,  NEDERLOF PETRA MARLEEN

Inventor： LINN SABINE CHARLOTTE ,  NEDERLOF PETRA MARLEEN

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/158 ,  C12Q2600/16

Abstract: Array comparative genomic hybridization classifiers, arrays comprising the classifiers and methods of using the same for differentiating between BRCA2-associated tumors and sporadic tumors by detecting phenotypic genetic traits using comparative genomic hybridization are disclosed.

Abstract translation: 公开了阵列比较基因组杂交分类器，包含分类器的阵列以及使用它们通过使用比较基因组杂交检测表型遗传性状来区分BRCA2相关肿瘤和散发性肿瘤的方法。

公开(公告)号：WO2010131962A3

公开(公告)日：2011-03-03

申请号：PCT/NL2010050277

申请日：2010-05-12

Applicant: STICHTING NL KANKER INST ,  OVAA HUIB ,  EL OUALID FARID

Inventor： OVAA HUIB ,  EL OUALID FARID

IPC: C07C271/22 ,  A61K31/198 ,  C07C323/59 ,  C07C391/00 ,  C07K1/13

CPC classification number: A61K38/02 ,  C07C271/22 ,  C07C323/59 ,  C07C391/00 ,  C07C2603/18 ,  C07K1/02

Abstract: The present invention concerns new thiolysine and selenolysine compounds that can be used as building blocks for peptides and proteins, providing ligation handles for site-and chemoselective modification of said peptides and proteins. In particular, the invention provides. In particular, the invention provides (the use of) the compounds 5-thiolysine (also referred to as d-thiolysine); 4-thiolysine (also referred to as ?-thiolysine); 5-selenolysine (also referred to as d-selenolysine) and 4- selenolysine (also referred to as ?-selenolysine). The positioning of the thiol or selenol group at the respective carbon atom allows for a very efficient intramolecular transfer reaction to take place after conjugation with a selected ligand, and the thiol or selenol group may subsequently be removed using reported procedures, thereby restoring the native lysine structure, or be used as an additional conjugation handle. The methodology is fast and gives well-defined material.

Abstract translation: 本发明涉及可用作肽和蛋白质的结构单元的新的硫代赖氨酸和硒代赖氨酸化合物，提供用于所述肽和蛋白质的位点和化学选择性修饰的连接手柄。 具体地，本发明提供。 特别地，本发明提供化合物5-硫代赖氨酸（也称为d-硫代赖氨酸）的用途（用途）。 4-硫代赖氨酸（也称为β-硫代赖氨酸）; 5-硒代赖氨酸（也称为d-硒代赖氨酸）和4-硒代赖氨酸（也称为α-硒代赖氨酸）。 硫醇或硒醇基团在相应碳原子上的定位允许在与所选择的配体缀合之后进行非常有效的分子内转移反应，并且随后可以使用报道的方法除去硫醇或硒酚基团，由此恢复天然赖氨酸 结构，或用作附加共轭手柄。 该方法很快，并提供了明确的材料。

公开(公告)号：GB201115211D0

公开(公告)日：2011-10-19

申请号：GB201115211

申请日：2011-09-02

Applicant: SLOTERVAART PARTICIPATIES BV ,  STICHTING NL KANKER INST

公开(公告)号：IL212606D0

公开(公告)日：2011-07-31

申请号：IL21260611

申请日：2011-05-01

Applicant: SANQUIN BLOEDVOORZIENING ,  STICHTING NL KANKER INST

IPC: C07K20060101

Abstract: The present invention relates to methods for detecting antigen responsive cells in a sample using multidimensional labeled antigen presenting compounds, such as antigen-major histocompatibility complexes (NHC). Further, the present invention relates to the use of the present multidimensional labeled antigen presenting compounds, such as antigen-major histocompatibility complexes (MHC), for detecting antigen responsive cells in a sample, preferably a single sample, such as a blood sample. The present method allows high-throughput analysis of specific antigen responsive cells, such as T- and B-cells, thereby providing, for example, high-throughput methods for monitoring of diseases or conditions and the development of immunotherapeutics, vaccines, or the identification epitopes or immunogenic amino acid sequences.

公开(公告)号：ES2398563T3

公开(公告)日：2013-03-20

申请号：ES06716584

申请日：2006-01-25

Applicant: STICHTING NL KANKER INST ,  SANQUIN BLOEDVOORZIENING

Inventor： OVAA HUIB ,  SCHUMACHER ANTONIUS NICOLAAS MARIA

IPC: C07K14/705 ,  C07K19/00

Abstract: Una molécula del complejo de histocompatibilidad mayor (MHC), que comprende un antígeno peptídico en elsurco de unión a péptidos de la molécula de MHC, por lo cual un grupo condicionalmente reactivo está presente enel antígeno peptídico que, cuando se activa por una señal física o química, rompe un enlace covalente dentro dedicho antígeno peptídico, que garantiza la liberación del antígeno peptídico de la molécula de MHC, y en la quedicho grupo condicionalmente reactivo comprende un grupo sensible a la luz o sensible al peryodato.

公开(公告)号：DK1841791T3

公开(公告)日：2013-02-04

申请号：DK06716584

申请日：2006-01-25

Applicant: STICHTING NL KANKER INST ,  SANQUIN BLOEDVOORZIENING

Inventor： OVAA HUIB ,  SCHUMACHER ANTONIUS NICOLAAS MARIA

IPC: C07K14/705 ,  C07K19/00